CagriSema and the REDEFINE 1 Numbers: What 20.4% Actually Means

You probably saw the number before you ever saw the name. A big weight-loss figure lands in a headline, your group chat forwards it, and suddenly everyone on a GLP-1 is quietly wondering whether they're already on yesterday's drug. The drug is CagriSema, the trial behind it is REDEFINE 1, and the moment you stop reading the headline and open the actual paper, a smaller number shows up instead — 20.4%. That gap between the two figures is the part almost nobody explains, and it's where most of the confusion lives.

So let's do what the headlines skip. CagriSema landed a genuinely large result. It's also not approved, not for sale, and not free of the same fine print that trails every drug in this family. Both of those things are true at the same time, and pretending otherwise is how people end up disappointed.

Two appetite switches in one pen

CagriSema is a once-weekly injectable that pairs two molecules: cagrilintide, an amylin analog, and semaglutide, the GLP-1 medicine you already know as Wegovy in its obesity dose. Neither name is a brand you can pick up at a pharmacy. The combination is still investigational, so it travels under its research name and its ingredients — nothing else.

The logic is simple enough to sketch on a napkin. GLP-1 drugs quiet hunger and slow how fast your stomach empties. Amylin is a separate hormone that works on fullness through a different door, helping signal to your brain that you've had enough. Put both pathways in one shot and the theory is that they add up to more than either could alone. Whether the theory holds isn't something you argue about. It's something a trial measures.

What REDEFINE 1 set out to test

REDEFINE 1 was a phase 3 trial built the way a serious one should be: 68 weeks long, double-blind, and controlled against both placebo and an active comparator. It enrolled adults living with overweight or obesity who did not have diabetes. A total of 3,417 people were randomized, with 2,108 of them assigned to receive cagrilintide-semaglutide.

None of those details are decoration. Double-blind means neither the participants nor the researchers knew who got the real drug, which keeps wishful thinking out of the math. The 68-week window matters because weight loss on these medicines doesn't wrap up in a month — the curve keeps bending for the better part of a year. And a sample in the thousands is large enough that a real effect is hard to mistake for a fluke.

That bottom row is the one that earns trust. More than two thousand people on the active drug for more than a year is the kind of foundation that holds up, rather than the small, exciting early study that looks thrilling and then quietly shrinks in a larger one.

The headline result

Here's the number the whole conversation is built on. At week 68, the estimated mean change in body weight was a 20.4% loss with cagrilintide-semaglutide, against a 3.0% loss with placebo. The estimated difference between the two groups came to 17.3 percentage points, with a 95% confidence interval running from −18.1 to −16.6.

In human terms: if you weighed 100 kg (about 220 lb) at the start, 20.4% is roughly 20 kg gone — somewhere around 45 lb. The placebo group's 3.0% is the reminder that just being in a structured trial, with check-ins and someone paying attention, nudges the scale a little on its own. The drug's real contribution is that 17.3-point gap stacked on top.

A confidence interval of −18.1 to −16.6 is tighter than most people realize. It means the trial didn't just stumble onto a big number once — it pinned that number down with very little wobble. The size of the drop is what drew attention; the narrow interval is why people trusted it wasn't a fluke.

The response curve tells the same story from another angle. People on cagrilintide-semaglutide were more likely than those on placebo to clear weight-loss thresholds of 5% or more, 20% or more, 25% or more, and even 30% or more — and the gap held at every rung (P less than 0.001 across the board). The 30% milestone is the one to sit with for a second. Significantly more people on the drug than on placebo lost nearly a third of their body weight on a weekly shot — that's the size of the signal, not a ranking against anything else.

Why you keep seeing two numbers

This is the part that trips people up, so it's worth slowing down. The 20.4% from the paper and the bigger figure you saw in the news aren't a contradiction, and one isn't a correction of the other. They answer two different questions, and trials now report both on purpose.

The 20.4% is the treatment-policy estimate. It asks the realistic question: across everyone assigned to the drug — including people who trimmed their dose, paused, or stopped entirely — how much weight actually came off? That's the figure that reflects what a population does in real life, messiness included. The larger number that made the headlines is the other estimate: what the result looks like if you assume everyone stayed fully on treatment the whole way through. It's a legitimate way to describe the drug's ceiling, and it usually runs higher.

Neither one is a lie. The honest move is to lead with the conservative figure, because it's the one closest to what you'd plausibly live — then keep the rosier number in view and know exactly where it comes from. When someone quotes only the bigger one without that context, they're not lying. They're just leaving half the sentence off.

How it stacks up against what's already here

This is where I have to let down anyone hunting for a clean "X% better than Wegovy" line. REDEFINE 1 wasn't only placebo-controlled — it was active-controlled too, with each ingredient tested on its own (cagrilintide alone and semaglutide alone) alongside the combination. The combination came out ahead of both of those single-ingredient arms. What the trial didn't do is pit the combination against a different drug like tirzepatide, so any precise "X% better than tirzepatide" percentage would be something I invented — and you don't want invented numbers about a drug you might one day weigh for yourself.

What you can say honestly is this: 20.4% over 68 weeks is a large drop, and within REDEFINE 1 the combination beat placebo and beat each ingredient on its own. It's a strong signal, full stop. But "strong in its own trial" and "proven better than the alternatives" are different claims, and only the first one is supported right now. Separate trials use different participants, different starting points, and different rules, so lining their numbers up side by side and crowning a winner is a sportswriter's move, not a scientist's. If you want a real verdict on whether it beats a different drug like tirzepatide, the only thing that delivers one is a direct head-to-head comparison — and that data isn't in yet.

The GI tradeoff nobody should skip

A 20% result that came free of side effects would be the only headline. It didn't. In REDEFINE 1, gastrointestinal adverse events showed up in 79.6% of the cagrilintide-semaglutide group, versus 39.9% on placebo. We're talking nausea, vomiting, diarrhea, constipation, and abdominal pain — the familiar GLP-1 lineup, turned up a notch.

Before that figure scares you off, read the rest of the sentence. These events were mainly transient and mild-to-moderate. In plain terms: for most people they arrived early, never turned severe, and faded as the body adjusted — the same arc anyone who's titrated up on a GLP-1 already recognizes. A rate that high is partly a product of asking carefully and counting everything, including a few queasy days that never became a real problem.

Still, four out of five isn't a rounding error, and it's nearly double the placebo rate. If the prospect of a rough first few weeks is the thing that would make you quit, that's exactly the conversation to have with a clinician before starting anything in this class — not a reason to panic, but a reason to plan.

It exists in trials, not in pharmacies

Here's the line that keeps everything above in proportion. As of 2026, CagriSema is not approved anywhere. It's an investigational drug, which means it lives inside clinical trials and regulatory review, not on a prescription pad. Realistic timelines point toward a possible approval in late 2026 or into 2027, and even that hinges on regulators agreeing the full data package holds up.

So if you've been tempted to chase it down through some gray-market channel, don't. There's no legitimate version to buy, the combination hasn't cleared the safety and manufacturing bar that approval represents, and "I saw a great trial number" is not the same as "a regulator signed off." The grown-up move with a promising investigational drug is to track it, raise it with your own clinician once it's actually available, and let the approval process do its job first.

The safety lines it inherits

Because CagriSema carries semaglutide inside it, it also carries semaglutide's warnings — and those are worth knowing now, not later. Acute pancreatitis, including serious cases, has been seen in people on GLP-1 receptor agonists, semaglutide among them. The standard guidance is blunt: if pancreatitis is suspected, the medicine is stopped. Persistent, severe abdominal pain isn't a side effect to wait out.

There's also a boxed warning. Semaglutide for weight management carries one for thyroid C-cell tumors, and it's contraindicated — off the table entirely — for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If that history runs in your family, this whole drug class is a no, and it belongs at the very top of any conversation about it.

None of this is a verdict that the drug is dangerous. It's the fine print riding along with the GLP-1 component, and knowing it ahead of time is how you walk into the conversation informed instead of worried.

If you're the type who's waiting

Plenty of people read a result like 20.4% and quietly think: maybe I should hold out and start on the better thing. It's a fair instinct, and also a trap worth naming out loud. CagriSema isn't available, and "late 2026 or 2027" is a forecast, not a delivery date. Postponing treatment you could begin now, for a drug that might arrive later and might land short of its best-case headline, is a wager against the version of your health you actually have today.

The steadier framing is to treat REDEFINE 1 as a signal about where this field is heading, not as a reason to put your own situation on hold. The pipeline is clearly pushing past first-generation GLP-1s, and that's good news worth being glad about. What it means for any one person — whether to start something now, whether this combination would even suit you later, how the side-effect math weighs against the benefit — is the kind of call that belongs in a room with a clinician who knows your history, not in a headline.

The honest bottom line

Cut through the noise and CagriSema is easy to sum up. In REDEFINE 1, it produced a 20.4% mean weight loss at 68 weeks against 3.0% on placebo — a 17.3-point separation, which is a large effect by any measure and one that also beat each ingredient on its own. The cost shows up as gastrointestinal side effects in 79.6% of people, mostly early and mostly manageable. It is not approved, not for sale, and it inherits semaglutide's real safety boundaries around pancreatitis and thyroid risk.

It's a genuinely interesting result, and worth watching closely — but not worth rearranging your health around today. Everything here comes from published clinical-trial and peer-reviewed data, not from anyone's testimonial or sales pitch — and whether any of it fits your situation is a question for a doctor who can see the whole picture. That's exactly the right place to take a number like 20.4% next.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app